Inactive Instrument

Relypsa Inc Stock

Equities

US7595311066

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets
- ^USD	-

on all our subscriptions*

Take advantage of the offer

* See conditions on site

Press releases Relypsa Inc

Relypsa : Announces Publication of Results of Veltassa Drug-Drug Interaction Studies in Journal of Cardiovascular Pharmacology and Therapeutics	17-02-13	PU
Relypsa Announces Data on the Treatment and Impact of Hyperkalemia to be Presented at ASN Kidney Week 2016	16-11-03	GL
Relypsa Announces Phase 4 Study Shows Veltassa® Demonstrated Similar Efficacy and Safety Whether Given With or Without Food in Patients with Hyperkalemia	16-08-30	GL
Relypsa : Acquisition May Not Be in the Best Interests of RLYP Shareholders	16-07-25	PR
RELYPSA, INC. Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Acquisition by Galenica May Be Unfair to Shareholders	16-07-22	BU

More press releases

Managers and Directors - Relypsa Inc

Managers	Title	Age	Since
David Bushinsky PRN	Corporate Officer/Principal	-	-
Gregory Oakes PRN	Corporate Officer/Principal	56	-

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW